O-acetylated sialic acid (SA) attached to the N-glycans of therapeutic glycoproteins reportedly inhibit sialidase activity, increase protein half-life, decrease protein antigenicity, and stabilize protein conformation. Recombinant human acid α-glucosidase (Myozyme) is the only drug approved by the United States Food and Drug Administration for the treatment of Pompe disease. In this study, unreported N-glycans containing O-acetylated SA in Myozyme and the relative quantities of total glycans were investigated using liquid chromatography (LC)-electrospray ionization (ESI)-high-energy collisional dissociation (HCD) tandem mass spectrometry (MS/MS). The 17 N-glycans (6.4% of total glycans) containing mono-, di-, mono/di-, and di/di-O-acetylated N-acetylneuraminic acid (Neu5Ac) were identified with mass accuracy, glycan-generated fragment ions, and the retention time on an LC column. The analysis of peptides containing mono- and/or di-O-acetylated Neu5Ac ions sorted from all peptides using nano-LC-ESI-HCD-MS/MS confirmed six O-acetylation sites (Asn 140, Asn 233, Asn 390, Asn 470, Asn 652, and Asn 882), at least five of which (Asn 140, Asn 233, Asn 390, Asn 470, and Asn 652) could contribute to the drug efficacy or cellular uptake of Myozyme. This is the first study to identify N-glycans containing O-acetylated Neu5Ac and O-acetylation sites in Myozyme.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpba.2019.03.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive Glycosylation Characterization of Recombinant Human Erythropoietin by Electron-Activated Dissociation Mass Spectrometry.
Appl Biochem Biotechnol
November 2024
SCIEX, Beijing, 100015, People's Republic of China.
Recombinant human erythropoietin (rhEPO) is a glycoprotein that acts as the main hormone involved in regulating red blood cell production to treat anemia caused by chronic kidney disease or chemotherapy, which has three N-glycosylation sites and one O-glycosylation site. It contains a variety of different glycosylation modifications, such as sialyation, O-acetylation on sialic acids, etc., which causes a big challenge for the glycosylation analysis of rhEPO.
View Article and Find Full Text PDFControl of resistance against bacteriophage killing by a metabolic regulator in meningitis-associated .
Proc Natl Acad Sci U S A
November 2022
Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, G12 8TA, United Kingdom.
Ecologically beneficial traits in bacteria are encoded by intrinsic and horizontally acquired genes. However, such traits are not universal, and the highly mosaic nature of bacterial genomes requires control at the transcriptional level to drive these processes. It has emerged that regulatory flexibility is widespread in the species, whereby preexisting transcription factors can acquire new and unrelated roles in regulating beneficial traits.
View Article and Find Full Text PDFComparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions.
Int J Mol Sci
June 2022
Merck Healthcare KGaA, 64293 Darmstadt, Germany.
Although the full primary structures of the alfa and beta subunits of reference r-hFSH-alfa and its biosimilars are identical, cell context-dependent differences in the expressing cell lines and manufacturing process can lead to variations in glycosylation profiles. In the present study, we compared the structural features of reference r-hFSH-alfa with those of five biosimilar preparations approved in different global regions outside Europe (Primapur, Jin Sai Heng, Follitrope, Folisurge, and Corneumon) with respect to glycosylation, macro- and microheterogeneity, and other post-translational modifications and higher order structure. The mean proportion of -glycosylation-site occupancy was highest in reference r-hFSH-alfa, decreasing sequentially in Primapur, Jin Sai Heng, Corneumon, Follisurge and Follitrope, respectively.
View Article and Find Full Text PDFIdentification of critical residues of O-antigen-modifying O-acetyltransferase B (OacB) of Shigella flexneri.
BMC Mol Cell Biol
March 2022
Division of Biomedical Science and Biochemistry, Research School of Biology, The Australian National University, Bldg.134, Linnaeus Way, Canberra, ACT, 2601, Australia.
Background: Shigellosis is an acute gastrointestinal disease caused primarily by the bacterium Shigella flexneri. Upon ingestion, S. flexneri initiates a serotype-specific immune response that targets the O-antigen of the pathogen's lipopolysaccharide.
View Article and Find Full Text PDFSite-specific N-glycan profiles of α β integrin from rat liver.
Biol Cell
June 2022
Institut Curie, Université PSL, Paris, France.
Background Information: Like most other cell surface proteins, α β integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
Results: Here, we have established the first comprehensive site-specific glycan map of α β integrin that was purified from a natural source, that is, rat liver. This analysis revealed striking site selective variations in glycan composition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!